Brought to you by 
UCSF grants uniQure rights to GDNF data for use with Parkinson’s gene therapy
07 Jan 2014
Executive Summary
The University of California, San Francisco, has licensed newly formed gene therapeutics start-up uniQure BV exclusive rights to preclinical and IND-enabling data generated by a therapy encoding the glial cell-derived neurotrophic factor (GDNF) gene for Parkinson’s disease. The company will also have access to clinical data.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
UCSF grants uniQure rights to GDNF data for use with Parkinson’s gene therapy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice